You are here

Soliris

EHA 2023 – Astrazeneca keeps up its complement defense

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Flag link:

Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3

Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3

Fierce Biotech

Flag link:

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

Fierce Biotech

Flag link:

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

Fierce Biotech

Flag link:

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Fierce Biotech

clinical trials

Flag link:

Could This Biosimilar Drug Candidate Be a Winner for Amgen?

Could This Biosimilar Drug Candidate Be a Winner for Amgen?

Motley Fool

Flag link:

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Endpoints

Flag link:

Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival

Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival

Endpoints

clinical trials

myasthenia gravis

Flag link:

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Fierce Pharma

myasthenia gravis

Flag link:

Genentech posts long-term data on near-approval Soliris rival

Genentech posts long-term data on near-approval Soliris rival

Fierce Biotech

Flag link:

Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report

Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report

Fierce Pharma

clinical trials

Flag link:

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Reuters

Apellis Pharmaceuticals

Alexion Pharmaceuticals

Flag link:

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Fierce Pharma

Flag link:

Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms

Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms

Xconomy

Alexion Pharmaceuticals

Flag link:

UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

Fierce Biotech

Ra Pharmaceuticals

Flag link:

After rocky hep C path, Achillion finds surer footing with FDA breakthrough status

After rocky hep C path, Achillion finds surer footing with FDA breakthrough status

Endpoints

paroxysmal nocturnal hemoglobinuria

Flag link:

Alexion shares slide on Amgen patent challenge to top-seller

Alexion shares slide on Amgen patent challenge to top-seller

Biopharma Dive

inter partes review

Flag link:

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Fierce Pharma

Flag link:

Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Flag link:

Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

Endpoints

autoimmune disease

Flag link:

Pages